Homocysteine in Alzheimer`s Disease and Related Disorders
|
|
- Reginald Shelton
- 6 years ago
- Views:
Transcription
1 Homocysteine in Alzheimer`s Disease and Related Disorders By Prof. Doaa Hamed Hewedi Professor of Psychiatry, Institute of psychiatry, Ain shams University
2 Introduction
3 -Worldwide, most people with AD and other dementias are cared for at home, usually by a spouse or a daughter. -In low-income and middle-income countries, the estimated proportion of people with dementia living at home is around 94%, compared with around 66% in high-income countries. -Several follow-up studies have consistently shown that the extent to which dementia shortens life expectancy depends on age at onset, gender, and dementia subtype. Gustavsson et al, and the ICTUS Study Group. Diff erences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study. J Nutr Health Aging 2010.
4 Life Expectansy In people aged 75 years or older, the effect of dementia on lifespan is similar to that of CVD, but lower than that of cancer. Years of life lost is an estimate of the average additional years a person would have lived if he or she had not died prematurely. It is an alternative to death or mortality rates, but gives more weight to deaths that occur among young people. Years of life lost can be estimated from the number of deaths multiplied by a standard life expectancy at the age at which death occurs. CVD=cardiovascular disease. WHO and Alzheimer s Disease International. Dementia: a public health priority. Geneva: World Health Organization, report_2012/en/ (accessed Jan 19, 2016).
5 Age-specific prevalence of dementia As shown by world region and in major countries Patterns of age-specific prevalence of dementia are similar across worldwide regions, but vary substantially among the oldest old (age 90 years). Prince et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013; 9:
6 Pathways to Alzheimer's disease Epidemiological and genetic studies of people with non-genetically determined (ie, sporadic) AD have identified mechanisms that might underlie brain Aβ accumulation, neuronal tau hyperphosphorylation, and synaptic deficits, ultimately leading to cognitive impairment and dementia AD=Alzheimer's disease. Aβ=amyloid β. Medina M & Avila J. New perspectives on the role of tau in Alzheimer s disease. Implications for therapy. Biochem Pharmacol 2014; 88:
7 In familial AD, the disease begins with Aβ pathology. It seems likely that different causative pathways result in distinct disease subtypes, which should be treated differently. The identification of subtypes of patients, with homogeneous pathogenesis and prognosis, will facilitate research and result in more accurate and personalised treatments for sporadic and familial AD Atagi Y, Liu CC, Painter MM, et al. Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 2015; 290:
8 Pathological changes associated with CSF biomarkers for Alzheimer's disease Schematic representation of a neuron, showing the pathological changes associated with the three core CSF biomarkers of Alzheimer's disease
9 - Increased CSF concentration of T-tau is a marker of axonal degeneration - Increased CSF concentration of P-tau suggests the presence of neurofibrillary tangles, and - Decreased CSF concentration of the 42-aminoacid form of Aβ (Aβ42) relates to senile plaque pathology. - In future, newly discovered CSF, blood, or brain imaging (eg, MRI, PET) biomarkers could allow early diagnosis, including the subtyping of Alzheimer's disease, and personalised-medical approaches to treatment and prevention. Blennow K, Zetterberg H. Understanding biomarkers of neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding. Nat Med 2015; 21:
10 Homocysteine Metabolism
11 Homocysteine (Hcy) is a sulfur containing amino acid synthesized in one carbon metabolic cycle. It is metabolized either by transsulfuration to cysteine or by remethylation to methionine. Several factors are known to increase Hcy level including male gender, older age, higher body weight, lower folic acid and vitamin B dietary intake, cigarette smoking, alcohol abuse, chronic renal disease, as well as certain medications such as diuretics and fibrates.
12 Interindividual differences in Hcy levels might be also attributed to certain genetic risk factors that influence the activity of one carbon metabolism. Primarily, high Hcy levels have been exclusively regarded as a risk factor for cardiovascular diseases. Indeed, it has been found that Hcy may lead to endothelial injury triggering a cascade of processes resulting in atherosclerosis.
13 Elevated mean levels of total Hcy were also found in a recent study of 24 patients with dystonia, as compared with controls (19.3 vs μmol/l), with a significant trend toward an association between the severity of dystonia and total Hcy. Previous experimental studies found that changes in Hcy levels are directly related to neurological disorders, such as MCI, AD, stroke, and movement disorders. Kim et al, Plasma homocysteine is associated with the risk of mild cognitive impairment in an elderly Korean population. J Nutr 2007; 137(9): Ho et al, Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta analysis, and metaregression. Am J Geriatr Psychiatry 2011; 19(7): Zhuo et al, Is hyperhomocysteinemia an Alzheimer s disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci 2011; 32(9):
14 Mechanisms of Homocysteine Action
15 Several mechanisms may underlie causative links between neurological disorders and higher Hcy levels. There are studies showing that high levels of Hcy may lead to dysfunction in glutaminergic & dopaminergic neurotransmission systems, which are altered in several brain disorders. Trimmer EE, Methylenetetrahydrofolate reductase: biochemical characterization and medical significance. Curr Pharm Des 2013; 19(14):
16 It has been reported that Hcy in high concentrations may serve as an agonist at the glutamate binding site and a partial antagonist at the glycine coagonist site within the NMDA receptors Further, Christie et al. have found chronic exposure to Hcy in rats impairs synaptic transmission. In addition, high Hcy levels may be toxic to dopaminergic neurons, which can perhaps explain the links between Hcy and dopamine related neurological disorders, such as PD or dystonia, as we discuss in the following Imamura et al, Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture. Neuroreport 2007; 18(13):
17 Mechanisms of homocysteine action as relevant to neurological disorders: Homocysteine may interact with NMDA receptors altering glutamatergic transmission Initiate endothelial damage, exert toxic effects on dopaminergic neurons Wang et al, Homocysteine induces apoptosis of rat hippocampal neurons by inhibiting epsilon expression and activating calcineurin. PloS One 2012; 7(11): e Kumar et al, Converging evidence of mitochondrial dysfunction in a yeast model of homocysteine metabolism imbalance. J Biol Chem 2011; 286(24):
18 Initiate neuronal apoptosis, induce oxidative stress Lead to mitochondrial dysfunction, and Influence DNA Methylation altering gene expression Dietrich Muszalska et al, The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem Res 2012; 37(5): Kinoshita et al, Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia. Epigenetics 2013; 8(6):
19 The link with cardiovascular disorders exists also in AD, since the brain vascular pathology with neuropathological hallmarks of AD and has been found to precede the onset of dementia. At the neural level, most existing studies found that variations in Hcy level affect the hippocampus. Cordonnier and van der Flier, Brain microbleeds and Alzheimer s disease: innocent observation or key player? Brain 2011; 134(Pt 2): Chen et al, Brain biochemical correlates of the plasma homocysteine level: a proton magnetic resonance spectroscopy study in the elderly subjects. Am J Geriatr Psychiatry 2011; 19(7):
20 Along the same lines, studies in rats found that hyperhomocysteinemia is associated with impaired performance in the Morris water maze task, which tests spatial learning and memory, and was found to rely on the hippocampus. Further, some studies also found that Hcy acts on the cortex & hyperhomocysteinemia leads to atrophy in the prefrontal cortex. Gao et al, Cognitive & neurochemical alterations in hyperhomocysteinemic rat. Neurol Sci 2011; 33(1): Redish and Touretzky, The role of the hippocampus in solving the Morris water maze. Neural Comput 1998; 10(1):
21 The exact neural and behavioral mechanism of Hcy is not known. Neural studies have shown that Hcy acts on various brain regions, including the hippocampus, the cortex, and the basal ganglia. Higher Hcy levels lead to atrophy in the frontal, parietal, and temporal areas. Rajagopalan et al, Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport 2011; 22(8):
22 Importantly, recent clinical trials are investigating the therapeutic efficacy of Hcy lowering drugs in AD patients (see gov). These studies and clinical trials stress the importance of understanding the relationship between Hcy and cognition. In the following, we review studies investigating the relationship between Hcy levels and symptom clusters in patients with neurological disorders.
23 Homocysteine and MCI
24 MCI is a state of cognitive decline greater than that expected for an individual s age and education level, but falling short of dementia. Clinical Dementia Rating (CDR) and Global Dementia Scale (GDS) are two commonly used clinical measures of memory impairment in MCI. Some studies define MCI based on a CDR score of 0.5, while others define it based on GDS score of 3. Smith et al, Homocysteine lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One 2010; 5(9): e12244.
25 Studies suggest that MCI may reflect gradual accumulation of dementia pathology, though at a level not yet sufficient to cause a catastrophic decline in cognitive function. This is particularly true of the MCI subgroup with memory loss as a predominant syndrome, a condition termed amnestic MCI. Gauthier et al, Mild cognitive impairment. Lancet 2006; 367(9518):
26 Individuals with amnestic MCI are at increased risk to develop AD within the next several years. Specifically, studies suggest that individuals with amnestic MCI tend to progress to AD at a rate of 10 15% per year, and many researchers consider it to be an early or prodromal form of AD. Along the same lines, many studies have shown that low levels of Hcy in individuals with MCI are protective against conversion to dementia. Morris et al, Mild cognitive impairment represents early stage Alzheimer disease. Arch Neurol 2001; 58(3):
27 There are few studies that have tested the relationship between cognitive function and Hcy levels in MCI. Most prior studies that have shown Hcy levels to be correlated with cognitive performance have used questionnaires rather than using DSM IV criteria
28 Recently, however, we found that total Hcy levels are higher in subjects with MCI than in healthy controls. In the same study, we found no difference between MCI individuals and healthy controls in a cognitive task that measures learning and generalization processes. However, we found that individuals with MCD make more generalization errors than healthy controls and individuals with vmcd (GDS = 2 & MCD, GDS = 3).
29 Our results are in agreement with prior results showing a link between hippocampal function, generalization performance, and total Hcy levels. Importantly, our study is perhaps among the first to test the relationship between learning (and generalization) of rules and Hcy levels in healthy controls and individuals with MCI. Moustafa et al, The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment. PLoS One 2012; 7(9): e46496.
30 Homocysteine and Alzheimer`s Disease
31 Blood total Hcy was examined in a British study of 30 patients aged 65 years and above, who were recruited from a psychogeriatric assessment center, all had a diagnosis compatible with the criteria for AD. The total Hcy level in the patients was highly significantly elevated in comparison to age matched controls [61]. McCaddon et al, Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998; 13(4):
32 Another British case control trial involved 164 patients with dementia found that the total Hcy was higher and both serum folate and vitamin B12 lower both in patients with AD and patients with histopathologically confirmed AD compared to controls. The association with total Hcy levels was independent of age, gender, social class, smoking habits, and the apoe4 genotype. Hvas et al, Increased plasma methylmalonic acid level does not predict clinical manifestations of vitamin B12 deficiency. Arch Intern Med 2001; 161(12):
33 Association with white matter hypoattenuation was calculated on the basis of 137 probable and definite AD (104 confirmed postmortem) patients, 38 cases of other types of dementia, and 279 controls, from whom a CT scan and total Hcy were obtained. White matter hypoattenuation was associated with age, dementia severity, cerebral infarcts, and systolic hypertension. Total Hcy was strongly associated with the severity of white matter hypoattenuation, and degree of atrophy. Hogervorst et al, Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002; 59(5):
34 Further, many studies have reported that lowering Hcy levels enhances memory and cognition in individuals with MCI and AD. Importantly, it was also shown that baseline measures of Hcy levels in AD patients and healthy subjects predict behavioral dysfunction in the future, as measured by the Cambridge Cognitive Testing Battery (CAMCOG), Mini Mental State Examination (MMSE), and the cognitive subscale of the Alzheimer s Disease Assessment Tool (ADAS Cog). Hvas et al, Increased plasma methylmalonic acid level does not predict clinical manifestations of vitamin B12 deficiency. Arch Intern Med 2001; 161(12):
35 Homocysteine and Vascular Dementia
36 Vascular dementia is considered the second most common type of dementia in the elderly after AD, and it is estimated to account for about 15% of dementia cases. Subcortical vascular encephalopathy is characterized by stepwise progressive memory deficits and cognitive decline, typical gait disorders, and incontinence. Sclerosis of small cerebral arteries and arterioles with diffuse periventricular white matter abnormalities and central lacunar lesions are observed in these patients.
37 In a recent study, patients with vascular dementia exhibited surprisingly high concentrations of total Hcy compared to controls and even to patients with cerebral macroangiopathy. This indicates that Hcy may cause injury to small cerebral arteries and arterioles rather than larger arteries. In this study, reduced levels of vitamin B12 and B6 were commonly present, and the levels of total Hcy correlated with the folate and vitamin B6 levels. Fassbender et al, Homocysteine in cerebral macroangiography and microangiopathy. Lancet 1999; 353(9164):
38 Vascular diseases may contribute to the pathogenesis of AD by lowering the threshold for overt cognitive impairment and dementia caused by pathophysiological mechanisms specific to AD. In one study, 101 patients who complained about cognitive disturbances were tested using the MMSE, laboratory investigation, brain imaging, and electroencephalography; 33% of the patients with subjective memory complaints, 45% of patients with AD, and 62% of the patients with vascular dementia had hyperhomocysteinemia ( 15 μmol/l).
39 The expected assumption that hyperhomocysteinemia should be more prominent in vascular dementia and age, tau protein levels, and prominent apoe4 alleles in AD was not confirmed, as hyperhomocysteinemia was common in both patient groups; vascular dementia and AD did overlap considerably. Gottfries et al, One carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis. J Geriatr Psychiatry Neurol 2001; 14(3):
40 A recent study found that elevated plasma total Hcy levels in patients with vascular dementia could only partly be attributed to cobalamin/folate deficiency or renal impairment. Several studies also found links between Hcy and stroke. The prevalence of hyperhomocysteinemia (>15 μmol/l) is less than 5% in a general population, but as high as 50% in patients with stroke. Stroke in these patients is accompanied by a higher rate of cerebral microangiopathy and multiple infarctions than in other stroke patients. Hankey and Eikelboom, Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications. CNS Drugs 2001; 15(6):
41 In a recent study, plasma Hcy levels were positively associated with the presence of ischemic stroke, but not coronary heart disease, in Chinese hypertensive patients. There was also a strong positive correlation between total Hcy and lipid peroxide and a strong negative correlation with the plasma concentration of ascorbic acid, which points to a Hcy related oxidative pathogenetic mechanism. Wang et al, Elevated plasma homocysteine level is associated with ischemic stroke in Chinese hypertensive patients. Eur J Intern Med 2014; 25(6): El Kossi and Zakhary, Oxidative stress in the context of acute cerebrovascular stroke. Stroke 2000; 31(8):
42 Homocysteine and Multiple Sclerosis
43 A negative correlation between serum vitamin B12 and the progression of MS is reported in the literature. More recently, total Hcy and vitamin B12 levels were measured, along with neurotransmitters and other variables in CSF of patients with MS. Total Hcy levels were highly significantly increased and vitamin B12 levels decreased in the CSF of MS patients compared to controls. Increased CSF levels of total Hcy in MS were also confirmed in a subsequent study. Qureshi et al, Multiple sclerosis and neurotransmission. Biog Amines 1996; 5: Baig et al, The interrelation between the deficiency of vitamin B12 and neurotoxicity of homocysteine with nitrite in some of neurologic disorders. Biog Amines 1998; 14: 1 14.
44 Serum levels of vitamin B12 and folate decreased in patients with relapsing remitting MS, but Hcy levels increased significantly. In addition, there were significant correlations between mean higher serum Hcy levels and duration of disease and treatment with β interferon. One study recommends to conduct prospective trials to determine whether the treatment with supplements and correct biomarker levels in the early stage of the disease can change the course of the disease and to perform regular checking of the serum level of Hcy in patients who use disease modifying drugs. Moghaddasi et al, Homocysteine, vitamin B12 and folate levels in Iranian patients with multiple sclerosis: a case control study. Clin Neurol Neurosurg 2013; 115(9):
45 Homocysteine and Parkinson`s Disease
46 Significantly elevated plasma levels of total Hcy have been reported in patients with PD [80 83]. In one study, the levels of Hcy were elevated by 60% in levodopa treated patients with a marked elevation occurring in patients with the MTHFR 677TT genotype. Another group has recently confirmed that plasma total Hcy levels are significantly higher in patients treated with levodopa (mean+sd; μmol/l) compared to patients not on levodopa ( μmol/l, p < ). Yasui et al, Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2000; 55(3):
47 Furthermore, this study showed that patients, whose plasma total Hcy levels were in the highest quartile (>17.7 μmol/l), had an increased prevalence of coronary artery disease. These findings have implications for the treatment of PD in patients at risk of vascular diseases and potentially for those at risk of dementia and depression as well. Rogers et al, Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60(1):
48 The effect of high Hcy levels on ventricular dilatation (percentage of intracranial volume (%ICV)) and total tissue volume at baseline and longitudinally after 36 months was studied where age, sex, education, and l dopa duration in PD patients were included as covariates. The study found that elevated Hcy levels correlated positively with ventricular dilatation (%ICV) (p = 0.008). At baseline, patients with a high Hcy level (>14 μmol/l) had higher ventricular volume (%ICV) than patients with a low Hcy level ( 14 μmol/l) (p = 0.03), which persisted over 36 months (p = 0.03). Sapkota et al, Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson s disease. Mov Disord 2014; 29(3):
49 Conclusion
50 There has been growing evidence in the last years, linking elevated Hcy levels with several neurological disorders. Moreover, Hcy, a nonprotein neurotoxic amino acid, has been proposed as a risk factor for cognitive decline in neurodegenerative disorders such as AD or PD but also in disorders with less established origins such as schizophrenia and bipolar disorder. Further research is warranted to unravel the molecular mechanisms underlying Hcy influence on nervous system damage and to clarify the role of Hcy in the etiology and prognosis of neurological symptomatology
51 It is also important to establish which mental disorders are linked with changes of Hcy levels in the blood plasma and whether the changes in Hcy concentrations depend on a clinical state of mental disorder (e.g., whether the disorder is in the early, middle, or late stage of progression or in remission). It is of great importance since there is some evidence showing that nutritional fortification with folic acid and vitamin B12, parallel to reduction of Hcy levels, may have influence on the course of the disorder and result in symptom reduction.
52 From genetic and genomic discoveries to precision medicine Starting with genetic and genomic discoveries, future research studies need to integrate data from all research areas to construct testable hypotheses and draw meaningful conclusions about the functional consequences of the known Alzheimer's disease genes and loci GWAS=genome-wide association study. WES=whole-exome sequencing. WGS=whole-genome sequencing.
53 These integrated analyses could push the research frontier forward, allow personal risk profiles to be generated, and ultimately help to shape individualised strategies for intervention. Defeating Alzheimer's disease and other dementias: a priority for European science and society Winblad, Bengt, Prof, Lancet Neurology, 2017, Volume 15, Issue 5,
54 THANK YOU
Fact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationImpact of vitamins & nutrients on neurological function. B-vitamins and aging. Nafisa Jadavji, PhD
Impact of vitamins & nutrients on neurological function B-vitamins and aging Nafisa Jadavji, PhD nafisa.jadavji@carleton.ca Lecture Outline Answer to questions from last class Homocysteine Vitamin B9:
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationHOW NUTRITION CHANGES THE AGING BRAIN. Nafisa Jadavji, PhD
HOW NUTRITION CHANGES THE AGING BRAIN Nafisa Jadavji, PhD NafisaJadavji@carleton.ca Lecture Outline Introduction Brain Nutrition Peer Review Questions BREAK Dementia and Alzheimer's disease Parkinson s
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationType 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky
Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationSecrets of delaying aging and living disease free Part 1
Secrets of delaying aging and living disease free Part 1 Roman Pawlak, Ph.D, RD www.drromanpawlak.com Aging results in profound changes that effect all systems, organs and tissues. Pawlak R. Forever young.
More informationUNIVERSITY OF WESTERN ONTARIO
UNIVERSITY OF WESTERN ONTARIO Vladimir Hachinski, CM, MD, FRCPC, DSc Department of Clinical Neurological Sciences University of Western Ontario London, Ontario, Canada Vladimir.hachinski@lhsc.on.ca ALZHEIMER
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationAnxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?
The 2016 Annual Public Educational Forum Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links? Mary Ganguli MD MPH Professor of Psychiatry, Neurology, and Epidemiology, University of
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationSupplementary Online Content
Supplementary Online Content Hooshmand B, Magialasche F, Kalpouzos G, et al. Association of vitamin B, folate, and sulfur amino acids with brain magnetic resonance imaging measures in older adults: a longitudinal
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet
ILSI Europe Satellite Workshop on Nutrition for the Ageing Brain: Towards Evidence for an Optimal Diet 03-04 July 2014, Milan, Italy Nutritional effects on cognitive ageing Trial data Dr. Ir. Ondine van
More informationSilent Cerebral Strokes: Clinical Outcomes and Management
Silent Cerebral Strokes: Clinical Outcomes and Management Nagaendran Kandiah Senior Consultant Neurologist, National Neuroscience Institute, Singapore Clinician Scientist, National Medical Research Council,
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by From Brains at Risk to Cognitive Dysfunction: The Role of Vascular Pathology Ralph Sacco, MD, MS, FAHA, FAAN Miller School of Medicine
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationB-Vitamins and the Ageing Brain
B-Vitamins and the Ageing Brain Helene McNulty PhD RD MRIA Director of the Northern Ireland Centre for Food, Nutrition and Health (NICHE) ulster.ac.uk Presentation Outline The Ageing Brain Evidence linking
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationPlasma Phospholipids Identify Antecedent Memory Impairment in Older Adults. Madeline Haff, Bikem Sonmezler, & Rosie Chu
Plasma Phospholipids Identify Antecedent Memory Impairment in Older Adults Madeline Haff, Bikem Sonmezler, & Rosie Chu So what exactly is Alzheimer s Disease? A progressive form of dementia that causes
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationA Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework
More informationThe Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
More informationInsulin and Neurodegenerative Diseases: Shared and Specific Mechanisms. Cogs 163 Stella Ng Wendy Vega
Insulin and Neurodegenerative Diseases: Shared and Specific Mechanisms Cogs 163 Stella Ng Wendy Vega Overview A. Insulin and the Brain B. Alzheimer s Disease and Insulin C. Other neurodegenerative disease:
More informationSignificant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy
Paterson, Abdi 1 Significant cognitive improvement with cholinesterase inhibition in AD with cerebral amyloid angiopathy Ross W Paterson MRCP 1 *, Zeinab Abdi MRCP 1 *, Amanda Haines RMN 1, Jonathan M
More informationThe Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults
The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults. Introduction Glucose intolerance is common in older individuals and this metabolic
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationThe Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease
The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease AIBL: Two site collaborative study Study is conducted at two sites: Perth
More informationBrain Health and Risk Factors for Dementia
Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00
More informationMEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH
MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH Nicci Kobritz, President Center for Brain Health & Youthful Aging Home Health 1 Our Goal Reduce the impact of modifiable medical risk factors associated
More informationALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
More informationOLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.
Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationDisorders of the Nervous System. Disorders of the Neurological System. General Endpoints of CNS Disease. General Endpoints of CNS Disease
HD in Nursing-Pathophysiology Disorders of the Nervous System What are some disorders of the nervous system? Disorders of the Neurological System Dr. C.H. Lai The nervous system is vulnerable to various
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationLowering the risk for Alzheimer s Disease Intake: Nutrition & AD. pspilman2015
Lowering the risk for Alzheimer s Disease Intake: Nutrition & AD 1 The Hippocampus Hippocampal & cortical brain regions are affected in AD. 2 The Neuron Neurons lose connections (synapses) Branches (dendrites)
More informationRound table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation
Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET
More informationNACC Minimum Data Set (MDS) Public Data Element Dictionary
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu
More informationParkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle
Parkinson s Disease in the Elderly A Physicians perspective Dr John Coyle Overview Introduction Epidemiology and aetiology Pathogenesis Diagnosis and clinical features Treatment Psychological issues/ non
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationThe role of the vascular system in dementia
The role of the vascular system in dementia James AR Nicoll Professor of Neuropathology, University of Southampton Consultant Neuropathologist, Southampton General Hospital What does the vascular system
More informationTUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationAT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE
AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a postprint version which may differ from the publisher's version. For additional information about this
More informationA Case of Vascular MCI
A Case of Vascular MCI Charles DeCarli, MD Victor and Genevieve Orsi Chair in Alzheimer s Research Director Alzheimer s Disease Center University of California at Davis Initial Evaluation 78 y.o. Rt. Handed
More informationSupplementary Note. Patient #1 Additional Details
Supplementary Note Patient #1 Additional Details Past medical history: The patient was ambidextrous. She had a history of hypertension, hyperlipidemia, migraines, and remote history of an ANA-positive
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationJohnson, V. E., and Stewart, W. (2015) Traumatic brain injury: Age at injury influences dementia risk after TBI. Nature Reviews Neurology, 11(3), pp. 128-130. (doi:10.1038/nrneurol.2014.241) There may
More informationRoger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana
Roger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana FINANCIAL DISCLOSURE No potential conflict of interest to disclose. OBJECTIVES
More informationreview of existing studies on ASL in dementia Marion Smits, MD PhD
review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More informationClinical Research on Treating Senile Dementia by Combining Acupuncture with Acupoint-Injection
Clinical Research on Treating Senile Dementia by Combining Acupuncture with Acupoint-Injection Yemeng Chen, M.D. Acupuncture Department, Huashan Hospital Shanghai Medical University, Shanghai 20040, P.
More informationRecent publications using the NACC Database. Lilah Besser
Recent publications using the NACC Database Lilah Besser Data requests and publications Using NACC data Number of requests by year Type 2009 2010 2011 2012 2013 2014 2015 Data files* 55 85 217 174 204
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationMULTIPLE CONCUSSIONS LEAD TO CHRONIC TRAUMATIC ENCEPHALOPATHY (CTE)
MULTIPLE CONCUSSIONS LEAD TO CHRONIC TRAUMATIC ENCEPHALOPATHY (CTE) CTE may develop within a short time of trauma but usually years intervene Symptoms Cognitive: depression, dementia Movement disorders:
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationFDA Perspective on Disease Modification in Schizophrenia
FDA Perspective on Disease Modification in Schizophrenia Robert Levin, M.D. Clinical Team Leader Division of Psychiatry Products Food and Drug Administration Goals and Expectations Develop treatments that
More informationMecanismo de acción de Souvenaid: nuevos datos preclínicos
Mecanismo de acción de Souvenaid: nuevos datos preclínicos Dra. Sagrario Manzano Coordinadora del Grupo de Neurología de la Conducta y Demencias de la SEN. Hospital Universitario Infanta Cristina. Parla.
More informationLipid Markers. Independent Risk Factors. Insulin Resistance Score by Lipid Fractionation
Patient: SAMPLE PATIENT DOB: Sex: MRN: 3701 CV Health Plus Genomics - Plasma, Serum & Buccal Swab Methodology: Chemiluminescent, Enzymatic, Immunoturbidimetric, NMR and PCR Lipid Markers Cholesterol LDL-
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationAssessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia
Assessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia AP Passmore Content Common dementia syndromes (older people)
More informationSerum Levels of Homocysteine, Vitamin B12, and Folic Acid in Patients with Alzheimer s Disease
IJMS Vol 34, No 3, September 2009 Original Article Serum Levels of Homocysteine, Vitamin B12, and Folic Acid in Patients with Alzheimer s Disease Fariba Karimi 1, Afshin Borhani Haghighi 2, Payman Petramfar
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationDisease Modification in Schizophrenia: Overview of the Issues. ISCTM February 18 th 2014 Ravi Anand, MD Switzerland
Disease Modification in Schizophrenia: Overview of the Issues ISCTM February 18 th 2014 Ravi Anand, MD Switzerland Need for a New Treatment Paradigm in Schizophrenia Sixty years after approval for the
More informationForm A3: Subject Family History
Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician
More informationPh D THESIS ABSTRACT
ALEXANDRU IOAN CUZA UNIVERSITY IAŞI FACULTY OF BIOLOGY THE STUDY OF CHANGES FOR SEVERAL BIOCHEMICAL PARAMETERS OF OXIDATIVE STRESS IN ANIMAL MODELS FOR NEUROPSYCHIATRIC DISORDERS Ph D THESIS ABSTRACT Scientific
More informationThe Person: Dementia Basics
The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationDementia: How to explain the diagnosis to patients and relatives
GPHot Topics (April 2017): Dementia: How to explain the diagnosis to patients and relatives mohammad somauroo Consultant Physician with specialist interest in Community Geriatrics Royal Liverpool and Broadgreen
More informationA Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies
A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationClinical Genetics & Dementia
Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer Nayana.lahiri@nhs.net Aims of the Session To appreciate the potential utility of family history
More information